BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for F Ma

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).EBI
East China University of Science and Technology
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.EBI
China Pharmaceutical University
Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis.EBI
Hangzhou Institute of Medicine (HIM)
Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout.EBI
HEC Research and Development Center
Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer.EBI
China Pharmaceutical University
Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.EBI
Peking Union Medical College
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors.EBI
Genentech
Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation.EBI
Novartis Institutes For Biomedical Research
Discovery of a Potent and Selective FLT3 Inhibitor (EBI
Nanjing University of Chinese Medicine
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.EBI
Xinyang Normal University
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.EBI
Novartis Institutes For Biomedical Research
Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation.EBI
Xinyang Normal University
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.EBI
Novartis Institutes For Biomedical Research
Alkyne substituted quinazoline compound and methods of useBDB
Newgen Therapeutics
Matriptase inhibitors and uses thereofBDB
SociÉTÉ
Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.BDB
Ondokuz Mayis University
Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.BDB
Pfizer